

MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Report - March 27, 2019

Visit Cutoff Date: March 27, 2019

. Visit Adherence: Completion of Procedures¹ by Site

	San Francisco
Participants Enrolled	19
1. Pelvic Examination Required and Expected	220
Completed	220 (100.0%)
2. hCG Required and Expected	37
Completed	37 (100.0%)
3. Dipstick UA Required and Expected	18
Completed	18 (100.0%)
4. Hemograms Required and Expected	37
Completed	37 (100.0%)
5. Differentials Required and Expected	37
Completed	37 (100.0%)
6. HIV-1 Serology Required and Expected	18
Completed	18 (100.0%)
7. Chemistries Required and Expected	55
Completed	55 (100.0%)
8. PK- Blood Required and Expected	221
Completed	221 (100.0%)
9. Plasma archive Required and Expected	19
Completed	19 (100.0%)
10. PK- Vaginal fluid Required and Expected	222
Completed	222 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit Case Report Form (CRF), the procedures for that visit will not be included as expected.

MTN 028 - Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Report - March 27, 2019

Visit Cutoff Date: March 27, 2019

. Visit Adherence: Completion of Procedures¹ by Site

	San Francisco
11. Cervical biopsy Required and Expected	18
Completed	18 (100.0%)
12. Gram stain Required and Expected	74
Completed	74 (100.0%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit Case Report Form (CRF), the procedures for that visit will not be included as expected.